Tecovirimat Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 200 mg
Reference Brands: TPOXX (USA), Tecovirimat SIGA (EU),
Category:
Anti Viral
Tecovirimat (also known as TPOXX or ST-246) is FDA-approved for the treatment of human smallpox disease caused by Variola virus in adults and children.
Tecovirimat is available in Capsules
and strengths such as 200 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Tecovirimat is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Tecovirimat can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Tecovirimat, marketed under the brand name TPOXX, is an antiviral medication with specific activity against orthopoxviruses, including smallpox and mpox. It made medical history in 2018 as the first antipoxviral drug approved in the United States, representing a major advancement in the treatment and preparedness for orthopoxvirus infections. Tecovirimat is designed to prevent the spread of virus within the body rather than directly killing the virus.
The drug works by inhibiting a viral protein involved in cellular transmission, effectively blocking the virus’s ability to exit infected cells and spread to healthy cells. This mechanism helps limit disease progression and supports the immune system in controlling the infection. Tecovirimat has demonstrated strong effectiveness in laboratory and animal studies, providing protection against infections such as mpox and rabbitpox.
Clinical experience has shown that tecovirimat is generally well tolerated in humans, with no serious side effects reported in studies. It was first used for human treatment in December 2018 following a laboratory-acquired vaccinia virus infection. Tecovirimat remains a critical therapeutic option for managing orthopoxvirus infections and enhancing global public health preparedness.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing